聚乙二醇干扰素β-1a(Peginterferon Beta-1a) - 药物靶点：IFNAR_在研适应症：多发性硬化症，复发-缓解型多发性硬化_专利_临床

概要

基本信息

药物类型

干扰素

别名

PEG-IFN-beta-1a、PEG-interferon-β-1a、PEGylated INF-beta-1a

+ [3]

靶点

IFNAR

作用机制

IFNAR激动剂(干扰素α/β受体复合体激动剂)、免疫调节剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Biogen Netherlands BV

Eisai Co., Ltd.

Biogen, Inc.

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

欧盟 (2014-07-18),

复发-缓解型多发性硬化

最高研发阶段(中国)-

特殊审评孤儿药 (韩国)

登录后查看时间轴

序列信息

Sequence Code 12364

来源: *****

关联

26

项与聚乙二醇干扰素β-1a 相关的临床试验

NCT06053749 / Active, not recruitingN/A

INFORM - Interferon-Beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-Based Drug Utilisation Study in Finland and Sweden

Observational data have suggested no increased risk of adverse pregnancy outcomes associated with exposure to interferon-beta (IFNB) before or during pregnancy. After the emergence of these data, the European Medicines Agency approved a label change for IFNB in September 2019, stating that use of IFNB during pregnancy may be considered, if clinically needed. However, limited data on pregnancies exposed in the 2nd and 3rd trimesters were observed.
INFORM is a secondary use of data drug utilisation study (DUS) to determine late pregnancy exposure (i.e. during the 2nd and 3rd trimester) to IFNB in Finland and Sweden, which will inform whether the number of exposed pregnancies is adequate to conduct a cohort study on adverse pregnancy outcomes, with a focus on late pregnancy exposure.
The number of pregnancies will be initially reported three years after the revised label implementation (September 2019) and will include data on pregnancies from 1996 in Finland and from 2005 in Sweden up through 31 December 2022. If the number of pregnancies is deemed adequate for conducting the cohort study on adverse pregnancy outcomes, this DUS will be finalised with the drug utilisation data accrued up through 31 December 2022. If the number of pregnancies until 31 December 2022 is deemed inadequate, this study may be continued and the primary and secondary objectives may be examined five years after the revised label implementation, including pregnancies until 31 December 2024.

开始日期2024-03-20

申办/合作机构

Bayer AG

[+3]

NCT05688436 / RecruitingN/A

Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

The primary objective of the study is to estimate the prevalence of major congenital malformations (MCMs) and compare the prevalence between the diroximel fumarate (DRF) and comparator groups. The secondary objectives of the study are to estimate the incidence of spontaneous abortion (SA) and compare the incidence between the DRF and comparator groups; to estimate the incidence of preterm birth and compare the incidence between the DRF and comparator groups; to estimate the incidence of stillbirth and compare the incidence between the DRF and comparator groups and to estimate the prevalence of small for gestational age (SGA) and compare the prevalence between the DRF and comparator groups.

开始日期2021-09-24

申办/合作机构

Biogen, Inc.

NCT04079088 / Withdrawn临床2期

A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 or Glatiramer Acetate Therapies in Relapsing Multiple Sclerosis

The primary objectives of the study are to evaluate the safety of BIIB061 versus placebo in participants with Relapsing Multiple Sclerosis (RMS), and to evaluate the efficacy of BIIB061 to improve disability outcome versus placebo in participants with RMS.
The secondary objectives of the study are to evaluate the effects of BIIB061 versus placebo on brain magnetic resonance imaging (MRI) markers of remyelination and axon preservation in chronic Multiple Sclerosis lesions and to evaluate the effects of BIIB061 versus placebo on additional measures of improved disability outcome.

开始日期2021-06-30

申办/合作机构

Biogen, Inc.

100 项与聚乙二醇干扰素β-1a 相关的临床结果

登录后查看更多信息

100 项与聚乙二醇干扰素β-1a 相关的转化医学

登录后查看更多信息

100 项与聚乙二醇干扰素β-1a 相关的专利（医药）

登录后查看更多信息

112

项与聚乙二醇干扰素β-1a 相关的文献（医药）

2024-10-01·Multiple Sclerosis and Related Disorders

Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY)

Article

作者: Saeidi, Morteza ; Ghiasian, Masoud ; Baghbanian, Seyed Mohammad ; Abolfazli, Roya ; Ayromlou, Hormoz ; Ghalyanchi Langroodi, Hamidreza ; Asadollahzadeh, Elnaz ; Shaygannejad, Vahid ; Beladi Moghadam, Nahid ; Ashtari, Fereshteh ; Kafi, Hamidreza ; Sabzvari, Araz ; Azimi Saeen, Amirreza

BACKGROUND:

Multiple sclerosis (MS) is a prevalent, disabling, inflammatory, neurodegenerative disease that typically manifests during a highly productive stage of life. Interferon beta-1a was among the first approved disease-modifying therapies for MS and remains among the first-line treatment options. Pegylation of the interferon beta-1a molecule prolongs its half-life while maintaining its efficacy and safety profile. In PEGINTEGRITY study, we aimed to compare peginterferon beta-1a with interferon beta-1a in terms of efficacy and safety in relapsing-remitting multiple sclerosis (RRMS) patients.

METHODS:

This study was a randomized, active-controlled, parallel-group, multi-center Phase 3 trial conducted in Iran in participants with RRMS. Participants received 125 µg of subcutaneous peginterferon beta-1a every two weeks or 30 µg of intramuscular interferon beta-1a once a week for up to 96 weeks. The primary outcome was the non-inferiority of peginterferon beta-1a to interferon beta-1a in reducing annualized relapse rate (ARR). Other outcomes included the number of patients with 12-week confirmed disability progression, the number of new or newly-enlarging T2 hyperintense lesions, the number of gadolinium-enhancing lesions, the number of new T1 hypointense lesions, the volume of new or newly-enlarging T2 hyperintense lesions, changes in brain volume, immunogenicity, and safety assessments.

RESULTS:

A total of 168 patients who met the eligibility criteria were enrolled and assigned to two arms of the study, each consisting of 84 participants. Totally, 41 participants (24 patients in the peginterferon beta-1a group and 17 patients in the interferon beta-1a group) were withdrawn from the study. The withdrawn patients were included in the per-protocol analysis for the period of time they were in the study. In 96 weeks, in the per-protocol population, the ARR was 0.05 in the peginterferon beta-1a group versus 0.11 in the interferon beta-1a group, which does not reflect a statistically significant difference (p=0.09; 95 % CI, 0.18-1.14). Considering the upper limit of the one-sided 95 % CI of the rate ratio of peginterferon beta-1a compared to interferon beta-1a, as well as the non-inferiority margin, it can be concluded that the primary outcome was met. The results were also comparable for other efficacy and safety outcomes.

CONCLUSION:

The results demonstrate the non-inferiority of peginterferon beta-1a to interferon beta-1a with similar efficacy in 96-week ARR in RRMS patients. Both arms were also comparable in other efficacy outcomes and safety profiles with no statistically significant differences. These findings support considering peginterferon beta-1a as a safe and efficient option in patients with RRMS. This study was registered on Iranian Registry of Clinical Trials (IRCT201612306135N8) and clinicaltrials.gov (NCT05242133).

2024-04-01·Multiple Sclerosis Journal-Experimental Translational and Clinical

Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program

Article

作者: Kumar, Achint ; Belviso, Nicholas ; Nelles, Gereon ; Koster, Thijs ; Salvetti, Marco ; Castro-Borrero, Wanda ; Wray, Sibyl ; Vignos, Megan

Background:

Interferon beta-1a remains an important treatment option for multiple sclerosis, particularly when safety or tolerability concerns may outweigh the benefits of higher-efficacy disease-modifying therapies. The five-year phase 4 Plegridy Observational Program (POP) study (NCT02230969) collected data on real-world safety and effectiveness of Plegridy® (peginterferon beta-1a) treatment in patients with relapsing multiple sclerosis.

Objective:

To explore the real-world safety and effectiveness of peginterferon beta-1a in patients with relapsing multiple sclerosis, including factors influencing treatment discontinuation.

Methods:

Data were collected prospectively from patients ≥ 18 years old with relapsing multiple sclerosis for overall population analysis and for subpopulations including newly/previously diagnosed patients, age, and experience with peginterferon beta-1a. Outcome measures included annualized relapse rates, adverse events, and predictors of time to treatment discontinuation.

Results:

Mean (SD) treatment duration in the overall population ( N = 1172) was 896.0 (733.15) days. Incidence of adverse events was higher in new than experienced users (79.4% vs. 57.0%). New users were more likely than experienced users to discontinue (hazard ratio = 1.60; P < 0.0001). The adjusted annualized relapse rate was 0.09, and at the end of 5 years, 77.1% of patients were relapse-free.

Conclusions:

Peginterferon beta-1a is an effective therapy for managing relapsing multiple sclerosis. The identification of predictors of discontinuation can help inform strategies to enhance treatment persistence.

2024-02-01·European review for medical and pharmacological sciences

Author Correction: Utilization of peginterferon-β-1a in the real-world practice for relapsing-remitting multiple sclerosis.

Article

作者: Brescia Morra, V ; Palladino, R ; Lanzillo, R ; Caliendo, D ; Triassi, M ; Moccia, M ; Rubba, F ; Santoni, L ; Affinito, G ; Vaccari, I

Correction to: European Review for Medical and Pharmacological Sciences 2024; 28 (1): 411-418. DOI: 10.26355/eurrev_202401_34930-published online on January 16, 2024. After publication, the authors have applied some corrections to the galley proof: • In the Patients and Methods section of the abstract, "National Health System" is corrected to "National Health Service". • In the Conclusions section of the abstract, "SC PEG-IFN-β-1a and IFN- β-1a" is corrected to "PEG-IFN-β-1a and SC IFN-β-1a". • In the Population section, the study period "January 1st 2015 to December 31st 2019" was not reported; therefore, this specification has been added to the text. • The legend of Figure 1 was wrongly reported as the same as Table I. The correct title of Figure 1 is "Study flow diagram". • Under Tables I, II, and III, "interferon beta 1a IFN-β-1a" is corrected to "interferon beta 1a (IFN-β-1a)". • In Table III, "CS Glatiramer acetate" is corrected to "SC Glatiramer acetate". • In the Conclusions section, "SC IFN-β-1a SC" is corrected to "SC IFN-β-1a". • The funding section has been amended as follows: "This study was sponsored by Biogen Italia (Milan, Italy)." There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/34930.

17

项与聚乙二醇干扰素β-1a 相关的新闻（医药）

2024-10-31

·Insight数据库

渤健 2024Q3：仑卡奈单抗卖了 6700 万美元，环比增长 66%

10 月 30 日，渤健发布 2024Q3 业绩，前三季度总营收 72.21 亿美元（-3%），其中产品收入 53.81 亿美元；第三季度营收 24.66 亿美元（-2.5%）。其中，用于阿尔兹海默病的 LEQEMBI（仑卡奈单抗）第三季度全球销售额约 6700 万美元，较上一季度增长 66%，其中美国市场销售额约 3900 万美元。截图来源：渤健财报仑卡奈单抗是全球首个获 FDA 完全批准的 AD 新药，今年三季度取得的进展如下： • 2024 年 7 月，卫材公布了 LEQEMBI 的 CLARITY AD 研究开放标签扩展的新临床数据，表明连续三年的 LEQEMBI 治疗减少了临床衰退，对早期阿尔茨海默病患者有临床意义的益处。 • 2024 年 6 月，FDA 接受了审查 LEQEMBI 每月静脉维持剂量治疗早期阿尔茨海默病的补充 BLA，PDUFA 行动日期定为 2025 年 1 月 25 日。 • 2024 年 5 月，在获得 FDA 快速通道资格后，卫材开始向 FDA 滚动提交 LEQEMBI 皮下自动注射的 BLA，用于每周维持剂量。多发性硬化症领域第三季度实现营收 10.54 亿美元同比 -9%。（主要产品包括 TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, 和 FAMPYRA）罕见病领域实现营收 4.95 亿美元，同比+10%。（主要产品包括SPINRAZA, SKYCLARYS 和 QALSODY）产后抑郁药物 ZURZUVAE（舒拉诺龙）第三季度收入约为 2200 万美元。截图来源：渤健财报渤健提高了 2024 年全年财务指引：截图来源：渤健财报维持 2024 年全年总收入较 2023 年全年下降个位数百分比的预期，核心药品收入预计与 2023 年全年大致持平；与 2023 年全年相比，目前预计营业收入将以较高的百分比增长，营业利润率将保持中等个位数的增长。重点产品前三季度销售额：截图来源：渤健财报封面来源：企业 Logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：vvy PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn 多样化功能、可溯源数据…… Insight 数据库网页版等你体验点击阅读原文，立刻解锁！

财报

2024-04-04

·PRNewswire

Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors

OKLAHOMA CITY, April 4, 2024 /PRNewswire/ -- Cadenza Bio, Inc., a pioneering preclinical biotechnology company dedicated to developing innovative small-molecule drugs for the treatment of multiple sclerosis (MS) and other demyelinating and inflammatory diseases, proudly announces the appointment of Michael A. Panzara, MD, MPH, to its esteemed board of directors. Dr. Panzara brings over 22 years of invaluable biopharmaceutical experience to Cadenza Bio. He currently serves as chief medical officer at Neurvati Neurosciences, a neuroscience-focused biotechnology company working to advance the development of clinical-stage product candidates for neurological and neuropsychiatric disorders. Prior to his role at Neurvati, Dr. Panzara held key leadership positions at Wave Life Sciences, Sanofi, Genzyme, and Biogen, showcasing his deep understanding of neurological disorders and drug development. He also serves on the board of directors of Athira Pharma, Inc., a neurology-focused clinical-stage biopharmaceutical company. Over his career, Dr. Panzara oversaw development activities and global regulatory approvals for several MS drugs. He served as the head of the Multiple Sclerosis, Neurology, and Ophthalmology Therapeutic Area for Global Development at Sanofi Genzyme, where he oversaw global regulatory approvals of LEMTRADA® (alemtuzumab) and AUBAGIO® (teriflunomide) and was responsible for development strategy and oversight within these therapeutic areas. During his time at Biogen, he served as global clinical lead for the development of TYSABRI® (natalizumab) for MS and managed clinical development activities for all late-stage MS products including AVONEX® (interferon beta-1a), PLEGRIDY® (PEG-interferon beta-1a), and TECFIDERA® (dimethylfumarate). "We are delighted to welcome Dr. Panzara to our board of directors," said Dr. Carol Curtis, chief executive officer of Cadenza Bio. "His extensive experience in developing therapies for MS and other neurological disorders aligns perfectly with our mission at Cadenza Bio. Dr. Panzara's strategic insights and deep understanding of the industry will be invaluable as we continue to advance our innovative drug pipeline and work towards bringing transformative treatments to patients in need." Dr. Panzara received his undergraduate degree in biology from the University of Pennsylvania and his medical degree from Stanford University School of Medicine. He completed his neurology training at Massachusetts General Hospital and received postdoctoral training in immunology and rheumatology at Brigham and Women's Hospital. Additionally, Dr. Panzara earned his master of public health degree from the Harvard School of Public Health. With Dr. Panzara joining the board of directors, Cadenza Bio is in a stronger position to achieve its goal of developing groundbreaking therapies for MS and other demyelinating and inflammatory diseases. "I look forward to joining the board of directors at Cadenza Bio at such an exciting time in the growth of the company," said Dr. Panzara. "Their approach in developing innovative dual-action therapeutic agents with neuroprotective and immunomodulatory effects has great potential to significantly expand our ability to address the unmet needs that remain for many MS patients." For more information about Cadenza Bio and its groundbreaking research, please visit . About Cadenza Bio, Inc. Cadenza Bio, Inc. is a preclinical biotechnology company focused on developing innovative small-molecule drugs for the treatment of demyelinating and inflammatory diseases. The company's mission is to break the cycle of disease and transform lives by developing therapies that not only alleviate symptoms but also halt progression, promote repair, and restore quality of life for patients. Cadenza Bio's MS drug pipeline, emerging from a collaboration between leading researchers, demonstrates promising preclinical results and offers hope for patients suffering from these debilitating conditions. SOURCE Cadenza Bio, Inc.

高管变更

2024-02-20

·药融圈

渤健财报解读

▲3月7-8日成都生物医药创新者峰会 · 点击立即报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。2月13日，美国biotech渤健公司发布了2023年财报，该公司全年营收98.36亿美元，同比下降2%，其中四季度营收23.86亿美元，同比下降6%。其业绩下滑的最主要原因是多发性硬化管线销售额下降，多发性药物共卖出54.30亿美元，同比下降14%。该公司在2023年的销售成本为25.33亿美元，占销售额的26%，毛利水平为74%，相比去年同期下降4%。研发投入24.62亿美元，约占销售额的25%，市场和一般管理费22.77亿美元，约占销售额的23%。因为毛利下降和研发投入增加，该公司的利润水平出现了明显下降，2023年净利润为11.62亿美元，仅为销售额的11.80%。渤健的业务营收分为三个部分，包括产品销售收入、产品授权费、CMO费，分别收入72.47亿美元、16.90亿美元和8.99亿美元。而产品销售收入又主要来自多发性硬化管线、罕见病管线和生物类似药管线，2023年净销售额分别为46.62亿美元、18.03亿美元和7.70亿美元。多发性硬化方面，富马酸二甲酯（TECFIDERA）因为专利已经失效，仅卖出10.13亿美元，相比去年同期销售额下降4亿多美元；VUMERITY是为了应对TECFIDERA专利悬崖而开发的505b2，全年卖出5.76亿美元，几乎相比去年同期持平。β干扰素（AVONEX）是渤健卖了20年的老产品，2023年营收8.11亿美元，相比去年同期也出现了下降。PLEGRIDY是AVONEX的升级品，2023年销售额为2.94亿美元，相比去年同期也存在下降。那他珠单抗(TYSABRI) 营收18.77亿美元，相比去年同期下降约2亿美元，氨吡啶缓释片(Fampridine）虽未出现销售额下滑，但营收不足1亿美元。罕见病管线方面，渤健拥有诺西那生钠(Spinraza）、Qalsody(tofersen)和Skyclarys(omaveloxolone)三款药物，全年营收分别为17.41亿美元、0.06亿美元和0.6亿美元，整个管线销售额几乎与去年持平。生物类似物方面，渤健主要有BENEPALI（依那西普）、IMRALDI（阿达木单抗）、英夫利昔单抗（FLIXABI）和BYOOVIZ（雷珠单抗）四款产品，2023年销售额分别为4.39亿美元、2.22亿美元、0.77亿美元和0.32亿美元，biosimilar总销售额几乎与去年同期持平。相关阅读诺和诺德2023年财报：司美格鲁肽大卖212亿美元诺华2023年业绩：营收454亿美元，同比增长10%GSK 2023年业绩：营收303亿英镑，盈利能力大幅提升辉瑞公布2023年业绩：营收同比下降42%，净利润同比下降93%强生2023年业绩公开，营收852亿美元，同比增长6.5%（附产品销售额）默沙东营收601亿美元，其中药王K药大卖250亿美元赛诺菲2023年营收431亿欧元，Dupixent突破110亿美元，氯吡格雷和甘精胰岛素在中国逆势增长再生元财报：度普利尤单抗卖出116亿美元，阿柏西普94亿美元艾伯维财报：修美乐销售额大幅下跌，正式让出药王宝座罗氏年报：营收下降7%，净利润下降9%礼来财报：GLP-1大卖125亿美元Vertex：囊性纤维化药物比增长11%，破百亿在即吉利德公开业绩：营收271亿美元，其中CAR-T 19亿美元安进2023年业绩：营收282亿美元，同比增长11%阿斯利康2023：中国区收入423亿元，增长7%BMS业绩：总营收450亿美元，同比下降2%版权声明：本文转自药事纵横，如不希望被转载的媒体或个人可与我们联系，我们将立即删除活动推荐 3月 • NDC x 2024新药创新者峰会关键词： ADC，改良型新药，小分子新药，GLP-1药物（点击下方图片查看详情）▼【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

财报生物类似药

100 项与聚乙二醇干扰素β-1a 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10483	聚乙二醇干扰素β-1a	L03AB13	DB09122

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
多发性硬化症	美国	Biogen, Inc.	2014-08-15
复发-缓解型多发性硬化	欧盟	Biogen Netherlands BV	2014-07-18
复发-缓解型多发性硬化	冰岛	Biogen Netherlands BV	2014-07-18
复发-缓解型多发性硬化	列支敦士登	Biogen Netherlands BV	2014-07-18
复发-缓解型多发性硬化	挪威	Biogen Netherlands BV	2014-07-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
流感样症状	临床3期	美国	Biogen, Inc.	2013-11-01
复发性多发性硬化	临床3期	美国	Biogen, Inc.	2009-06-01
复发性多发性硬化	临床3期	比利时	Biogen, Inc.	2009-06-01
复发性多发性硬化	临床3期	保加利亚	Biogen, Inc.	2009-06-01
复发性多发性硬化	临床3期	加拿大	Biogen, Inc.	2009-06-01
复发性多发性硬化	临床3期	智利	Biogen, Inc.	2009-06-01
复发性多发性硬化	临床3期	哥伦比亚	Biogen, Inc.	2009-06-01
复发性多发性硬化	临床3期	克罗地亚	Biogen, Inc.	2009-06-01
复发性多发性硬化	临床3期	捷克	Biogen, Inc.	2009-06-01
复发性多发性硬化	临床3期	爱沙尼亚	Biogen, Inc.	2009-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


German Multiple Sclerosis and Pregnancy Registry (ECTRIMS2023)	N/A	多发性硬化症	247	Interferon beta-1a	齋簾網獵選夢衊餘窪獵(鹽製醖繭網夢醖齋觸蓋) = comparable between exposed children and controls during the observation period 淵糧膚壓鏇襯顧鹽餘蓋 (繭窪醖鹹衊選選構鑰艱 ) 更多	积极	2023-09-30
NCT03870763 (CTgov)	临床3期	复发-缓解型多发性硬化	11	Dimethyl Fumarate (Dimethyl Fumarate 240 mg)	構艱齋鏇鏇壓淵範範觸(選鑰獵壓簾壓鹹壓糧餘) = 餘膚築糧壓觸範築鑰繭顧艱艱醖窪簾醖艱壓廠 (糧艱製淵鹹膚餘構鑰襯, 構蓋製糧鑰願淵製廠觸 ~ 獵顧廠鏇積齋淵蓋醖遞) 更多	-	2023-05-16
				Peginterferon Beta-1a (Peginterferon Beta-1a 125 µg)	構艱齋鏇鏇壓淵範範觸(選鑰獵壓簾壓鹹壓糧餘) = 襯艱餘糧鏇獵遞範選製顧艱艱醖窪簾醖艱壓廠 (糧艱製淵鹹膚餘構鑰襯, 壓窪憲夢餘顧選夢糧襯 ~ 艱糧鏇築淵觸糧製襯蓋) 更多
German Multiple Sclerosis and Pregnancy Registry (ECTRIMS2022)	N/A	多发性硬化症	70	Interferon-beta 1a exposure during pregnancy	簾憲遞鏇淵艱醖簾糧構(艱觸憲製範鏇膚餘齋淵) = 夢獵衊繭醖遞獵餘選衊餘糧築網積範艱範蓋遞 (選糧鹽構淵餘餘壓構觸 )	积极	2022-10-12
Plegridy Observational Program (ECTRIMS2021)	N/A	复发性多发性硬化	1,208	Peginterferon beta-1a	壓獵獵鏇繭構廠鏇鑰壓(廠廠齋窪艱積襯糧製衊) = 築網網淵窪選衊顧餘獵遞鹹願觸鏇廠糧築衊鹹 (顧獵壓顧襯築繭簾網齋 ) 更多	积极	2021-10-12
				Placebo	壓獵獵鏇繭構廠鏇鑰壓(廠廠齋窪艱積襯糧製衊) = 製餘鏇壓願廠夢獵艱憲遞鹹願觸鏇廠糧築衊鹹 (顧獵壓顧襯築繭簾網齋 ) 更多
IMSE 6 (ECTRIMS2021)	N/A	-	393	Peginterferon beta-1a	鬱蓋製鑰鹹積願壓蓋觸(鹹鑰鹽鏇淵製鬱顧衊獵) = General disorders and administration site were also the most common for non-serious AEs (68%) 糧夢鹽繭醖遞夢襯願窪 (艱鏇膚餘選製窪齋鹹顧 ) 更多	积极	2021-10-12
NARCOMS (ECTRIMS2020)	N/A	复发性多发性硬化	-	Intramuscular interferon beta-1a	選廠鑰襯憲選鏇獵衊繭(網網積壓壓獵齋鏇範網) = 範鹽餘蓋鑰襯鹹製憲憲襯鑰顧鏇鹹繭鬱餘鹽鹽 (糧糧憲襯願選築鹹憲繭 ) 更多	积极	2020-12-07
				Peginterferon beta-1a	選廠鑰襯憲選鏇獵衊繭(網網積壓壓獵齋鏇範網) = 鑰獵顧餘積願鑰鹹鏇膚襯鑰顧鏇鹹繭鬱餘鹽鹽 (糧糧憲襯願選築鹹憲繭 ) 更多
ECTRIMS2020	N/A	-	-	Peginterferon beta-1a	蓋窪製獵壓壓蓋衊壓餘(餘築蓋積壓鹽憲範廠繭): ARR ratio = 1.18 (95% CI, 0.72 ~ 1.94), P-Value = 0.5047 更多	-	2020-12-07
				Non-pegylated interferons
ECTRIMS2020	N/A	多发性硬化症	2,479	Peginterferon beta-1a	鹽膚餘鏇築顧膚齋簾範(膚築廠廠築築廠選鏇糧) = 鹹築醖醖餘鹽鏇獵廠淵選範衊積顧壓遞窪襯衊 (鏇顧膚艱築繭繭鹽淵廠 ) 更多	-	2020-12-07
				Intramuscular interferon beta-1a	顧襯簾鏇觸積憲衊鹹願(糧網憲網窪襯淵繭壓襯) = 淵積鏇範膚衊顧餘積鏇願觸鏇鹽選獵蓋衊膚積 (醖壓選窪淵鑰糧襯網衊 )
IMSE 6 (ECTRIMS2020)	N/A	-	364	Peginterferon beta-1a	繭壓顧觸遞範鏇網繭積(衊網艱築窪觸簾淵鑰壓) = A total number of 18 adverse events (6 serious) were reported to Swedish Medical Product Agency. 餘廠簾繭艱網積鏇繭遞 (鑰獵齋積觸遞網壓膚鑰 )	-	2020-12-07
MS PATHS (ECTRIMS2020)	N/A	-	817	Peginterferon beta-1a	艱夢衊壓遞獵齋獵鹽網(簾齋鹽範遞鹽壓襯壓艱) = 夢構餘觸遞窪繭鏇獵醖願製壓艱觸襯觸網齋鑰 (夢憲襯網糧積遞構網繭 ) 更多	积极	2020-12-07
				Intramuscular interferon beta-1a	艱夢衊壓遞獵齋獵鹽網(簾齋鹽範遞鹽壓襯壓艱) = 顧構鏇壓窪製獵壓鑰餘願製壓艱觸襯觸網齋鑰 (夢憲襯網糧積遞構網繭 ) 更多